Array gains on Phase III OS data in melanoma

Array BioPharma Inc. (NASDAQ:ARRY) gained $2.19 (16%) to $16.28 on Tuesday after reporting that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial to treat BRAF V600 mutation-positive melanoma. In the 921-patient trial, twice-daily 45 mg binimetinib plus once-daily 450 mg encorafenib led to a median OS of 33.6 months vs. 16.9 months for Zelboraf (HR=0.61, 95% CI: 0.47, 0.79, p<0.001).

The two-part trial enrolled patients with BRAF V600 mutation-positive locally advanced, unresectable or metastatic melanoma and evaluated binimetinib plus encorafenib compared to Zelboraf and encorafenib monotherapy...